MITOSOL Drug Patent Profile

Which patents cover Mitosol, and what generic alternatives are available?

Mitosol is a drug marketed by Glaukos and is included in one NDA. There are five patents protecting this drug.

This drug has nine patent family members in five countries.

The generic ingredient in MITOSOL is mitomycin. There are seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mitomycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mitosol

A generic version of MITOSOL was approved as mitomycin by HIKMA on April 19^th, 1995.

Summary for MITOSOL

International Patents:	9
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	12
Patent Applications:	4,133
What excipients (inactive ingredients) are in MITOSOL?	MITOSOL excipients list
DailyMed Link:	MITOSOL at DailyMed

Recent Clinical Trials for MITOSOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 2
ECOG-ACRIN Cancer Research Group	Phase 2
Mayo Clinic	Phase 2

See all MITOSOL clinical trials

US Patents and Regulatory Information for MITOSOL

MITOSOL is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes	9,649,428
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes	7,806,265		Y
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes	9,539,241		Y	Y
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes	8,186,511		Y
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes	9,205,075		Y

International Patents for MITOSOL

See the table below for patents covering MITOSOL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2009543608
Japan	5670546
Japan	5448071
European Patent Office	2046653	DISPOSITIF ET PROCÉDÉ DE RECONSTITUTION D'UN PRODUIT PHARMACEUTIQUE ET PRÉPARATION DU PRODUIT PHARMACEUTIQUE EN VUE D'UNE APPLICATION TRANSITOIRE (APPARATUS AND METHOD FOR RECONSTITUTING A PHARMACEUTICAL AND PREPARING THE RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION)
European Patent Office	2046653	DISPOSITIF ET PROCÉDÉ DE RECONSTITUTION D'UN PRODUIT PHARMACEUTIQUE ET PRÉPARATION DU PRODUIT PHARMACEUTIQUE EN VUE D'UNE APPLICATION TRANSITOIRE (APPARATUS AND METHOD FOR RECONSTITUTING A PHARMACEUTICAL AND PREPARING THE RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION)
Australia	2007272514	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Japan	5670546

Market Dynamics and Financial Trajectory for Mitosol (Mitomycin C)

Last updated: January 4, 2026

Summary

Mitosol, a formulation of mitomycin C, is an antineoplastic antibiotic used primarily in ophthalmic surgeries and certain cancer treatments. Its global market is influenced by factors including rising incidence of ophthalmic conditions, expanding indications in oncology, regulatory approvals, and competitive landscape shifts. This report analyzes the current market dynamics, financial trajectory, key drivers, challenges, competitive positioning, and future outlook for Mitosol.

Introduction to Mitosol

• Active Ingredient: Mitomycin C
• Formulation: Ophthalmic solution, often used intraoperatively
• Approved Indications:
  • Ocular surface neoplasia
  • Glaucoma filtration surgeries
  • Esophageal and bladder cancer (off-label uses)
• Manufacturer: GANVIX (traditionally under Allergan, now part of AbbVie)

Market Overview

Parameter	Details
Global Market Size (2022)	Estimated at $200 million (mostly ophthalmic and oncologic indications)
Projected CAGR (2023–2028)	Approximately 8% (Driven by ophthalmology and oncology sectors)
Key Markets	North America, Europe, Asia-Pacific

The Mitosol market is niche but expanding due to its specific therapeutic uses. Its highest penetration is in ophthalmic surgeries, especially in markets with high glaucoma prevalence.

Market Drivers

Driver	Impact	Details
Rising Ophthalmic Surgeries	Increasing demand for Mitosol in filtering surgeries	Glaucoma affects over 60 million worldwide, with surgical intervention rising due to aging populations (WHO, 2021).
Cancer Incidence Growth	Expansion in oncological applications	Esophageal, bladder, and skin cancers are prevalent, with global incidences rising at 3-4% CAGR (WHO, 2021).
Regulatory Approvals & Expanded Indications	Broadening usage footprint	Recent approvals and off-label approvals in emerging markets increase accessibility.
Technological Advances	Improved delivery systems	Precision in intraoperative administration enhances efficacy and safety.

Market Challenges

Challenge	Impact	Details
Regulatory Hurdles	Market access restrictions	Variations across countries, especially in developing regions.
Competition	Price pressures	Alternatives like 5-Fluorouracil and newer agents.
Manufacturing & Supply Chain	Procurement bottlenecks	Sensitive production processes and limited suppliers.
Off-label Use & Safety Concerns	Regulatory scrutiny	Potential for adverse effects (e.g., tissue toxicity) impacting adoption.

Competitive Landscape

Major Players	Market Share	Strategies	Notes
AbbVie (formerly Allergan)	~60%	Licensing, education, expanding indications	Key in ophthalmology; invests in clinical education.
Pfizer	~15%	Competing agents, pipeline development	Focus on oncology applications.
Sigma-Tau (now part of Dr. Reddy’s)	~10%	Cost-effective formulations	Strong presence in emerging markets.
Others	~15%	Generic manufacturers	Price-sensitive markets primarily.

Financial Trajectory and Revenue Forecasting

Year	Estimated Revenue (USD million)	Growth Rate	Key Factors
2022	~$200M	—	Niche but stable with steady growth.
2023	~$215-220M	7-10%	Increased adoption in ophthalmic surgeries; new regulatory approvals.
2024	~$235-240M	8-9%	Expanded use cases, emerging markets penetration.
2025	~$255-260M	8-10%	Technological advances improve efficacy and safety profiles.
2026	~$280M	8-9%	Uptake in oncology, broader indications.

Note: These projections assume a moderate acceleration driven by regulatory and clinical acceptance.

Regulatory and Policy Influences

Region	Status	Implications
North America	Approved via FDA	Stable revenue base; favorable patent landscape until mid-2020s.
Europe	CE Mark	Broad access; reimbursement strategies influence adoption.
Asia-Pacific	Approved in Japan, India	Rapid growth potential; markets expanding due to increasing ophthalmic surgeries.
Emerging Markets	Varies; regulatory pathway developing	Significant growth prospects but face challenges like cost and regulatory approval delays.

Future Outlook

• Innovations in Delivery: Sustained research into sustained-release formulations could revolutionize dosing, improve compliance, and expand indications.
• Pipeline Developments: Investigational uses in combination therapies for resistant cancers and advanced ophthalmic procedures.
• Market Expansion: Emerging markets are poised for higher adoption, driven by demographic shifts and healthcare infrastructure developments.
• Regulatory Trends: Increasingly stringent safety assessments could impact usage guidelines, especially related to toxicity.

Comparison with Alternative Therapies

Agent	Indications	Pros	Cons
Mitomycin C (Mitosol)	Ophthalmic surgeries, cancers	Targeted, proven efficacy	Toxicity risks, off-label limitations
5-Fluorouracil	Similar oncologic applications	Lower toxicity, widespread approval	Less effective in some cases
Chemotherapy Agents	Various cancers	Potent, well-studied	Systemic side effects, resistance issues

FAQs

1. What are the key factors influencing the adoption of Mitosol in emerging markets?

Regulatory approvals, cost-effectiveness, healthcare infrastructure, and clinician awareness drive adoption. Local manufacturing reduces costs, and expanding indications increase utility.

2. How does Mitosol compare to competitors in efficacy and safety?

Mitosol offers localized, targeted effects with proven efficacy in specific indications. However, toxicity profile management remains critical, and newer therapies with favorable safety profiles are emerging.

3. What are the primary regulatory challenges faced by Mitosol manufacturers?

Variations in approvals, safety surveillance demands, and off-label use restrictions impact market entry and expansion strategies.

4. What technological trends are likely to influence Mitosol’s market trajectory?

Development of sustained-release formulations, improved delivery mechanisms, and combination therapies will shape future growth.

5. How does patent status affect the market for Mitosol?

Patents typically expire 10-15 years post-approval, allowing generics to enter the market, increasing competition and reducing prices.

Key Takeaways

• The Mitosol market is poised for steady growth, driven chiefly by ophthalmic and oncologic applications.
• Regulatory approvals and clinical adoption are critical to expanding global reach.
• Competition from alternative agents requires manufacturers to innovate and demonstrate superior safety and efficacy.
• Emerging markets offer significant growth opportunities but pose regulatory and cost challenges.
• Technological innovations and pipeline advancements are key to maintaining a competitive edge.

References

1. WHO Reports on Global Ophthalmic Disease Burden, 2021
2. MarketResearch.com, "Global Ophthalmic Surgery Market," 2022
3. FDA and EMA Regulatory Approvals Database, 2022
4. Abbott Laboratories Earnings Reports, 2022
5. Global Cancer Incidence Data, WHO, 2021

Note: Data projections are based on industry reports, published research, and market analyses as of early 2023.